Last update Sept. 5, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Diosmin is also known as
Diosmin in other languages or writings:
Diosmin belongs to these groups or families:
Main tradenames from several countries containing Diosmin in its composition:
|T½||26 - 43||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Flavonoid compound. Flavonoids are phenolic compounds naturally occurring that are abundantly present in all plants and in some seaweed.
They are ingested when drinking fruits, vegetables, tea and red wine, for example. (Serafini 1996)
Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins.
Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012, AESAN 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins) and prevention of arteriosclerosis.
They appear naturally in the breast milk in amounts related to mother's diet. (Romaszko 2014, Song 2013)
No risk for toxic nor side-effects in humans have been found (AESAN 2012). No problems have been observed in infants whose mothers were treated with troxerutin. (Krajnovic 1977)
Some flavonoids such as diosmin and hydrosmin are classified as having low therapeutic utility. (GFD 2011)